Regentis Biomaterials Ltd. (RGNT) Fair Value 2026

RGNT · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.3 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (36/100)

Quick Summary — As of 2026-08-28, Regentis Biomaterials Ltd. (RGNT) trades at $2.00. QOC: 4.3/10. Value Trap Risk: 36/100 (LOW). 1/13 models active.

Key Facts

Ticker
RGNT
Price
$2.00
Quality Score
4.3/10
Value Trap Risk
36/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.3/10 signals weak fundamentals

What Fair Value Does Each Model Give RGNT?

1 Intrinsic Value Models vs. Current Price ($2.00)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · Medium Conviction
 $1.27 -36.3%

All Models Active

All 1 models are displayed above.

What Is Regentis Biomaterials Ltd. (RGNT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Regentis Biomaterials Ltd.'s intrinsic value is estimated at $1.27, suggesting the stock is overvalued at its current price of $2.00. With 1 out of 1 models flagging downside (-36.3% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About RGNT?

1 of 13 models are currently active for RGNT. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does RGNT Rank in Medical Instruments & Supplies?

Among 56 Medical Instruments & Supplies stocks, RGNT ranks #51 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.

See all Most Undervalued Medical Instruments & Supplies Stocks →

Regentis Biomaterials Ltd. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is RGNT a Value Trap?

CirclFi's Value Trap algorithm assigns RGNT a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Regentis Biomaterials Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Regentis Biomaterials Ltd.'s fundamental quality profile registers 4.3/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RGNT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across RGNT's 1 active models, average confidence is 36%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Regentis Biomaterials Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

11 related Medical Instruments & Supplies stocks with 13-model coverage

YBGJYubo International Biotech LimitedQOC 4.5UEECUnited Health Products, Inc.QOC 4.1DXRDaxor CorporationQOC 4.6TUTHStandard Dental Labs Inc.QOC 3.2PLSEPulse Biosciences, Inc.QOC 5.3ZJYLJin Medical International Ltd.QOC 2.9ALGNAlign Technology, Inc.QOC 8.4SMTISanara MedTech Inc.QOC 7.1POCIPrecision Optics Corporation, Inc.QOC 6.1ISRGIntuitive Surgical, Inc.QOC 9.4RMDResMed Inc.QOC 9.4

Read investment analysis: YBGJ · UEEC · DXR · TUTH · PLSE · ZJYL · ALGN · SMTI · POCI · ISRG · RMD

Which Other Stocks Have a Similar Quality Score to RGNT?

7 companies across all industries closest to RGNT’s Quality of Company score of 4.3/10.

CLDICalidi Biotherapeutics, Inc.QOC 4.3ENVBEnveric Biosciences, Inc.QOC 4.3SATTSativus Tech Corp.QOC 4.3KRFGKing Resources, IncQOC 4.3MEDSDataMEDS AI, Inc.QOC 4.3LTUMLithium CorporationQOC 4.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CLDI · ENVB · SATT · KRFG · MEDS · LTUM · NVDA

Where Does RGNT Sit in CirclFi's Medical Instruments & Supplies Rankings?

RGNT is ranked against every other Medical Instruments & Supplies stock CirclFi covers in each of these screens.

See all Medical Instruments & Supplies stocks ranked →

What Else Do Investors Ask About Regentis Biomaterials Ltd.’s Valuation?

What is Regentis Biomaterials Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Regentis Biomaterials Ltd. (RGNT). The Quality of Company score is 4.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RGNT overvalued or undervalued right now?

At $2.00, 0 of 1 active models suggest RGNT may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Regentis Biomaterials Ltd.'s business model in Medical Instruments & Supplies.

What does a Quality of Company score of 4.3 mean for RGNT?

Regentis Biomaterials Ltd.'s QOC of 4.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on RGNT?

CirclFi analyzes RGNT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is RGNT a value trap in 2026?

Regentis Biomaterials Ltd.'s Value Trap score is 36/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Regentis Biomaterials Ltd. (RGNT) a Quality of Company score of 4.3/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/RGNT/ · Methodology
Primary sources for this RGNT valuation
  • Financial statements: Regentis Biomaterials Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001912966) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for RGNT as of ; valuations recomputed .